No Data
Hangzhou Tigermed Consulting's (SZSE:300347) Soft Earnings Are Actually Better Than They Appear
Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks
Zhongtai: Innovative Drugs lead the market, pay attention to Q1 performance + policy catalysis.
In April, the pharmaceutical Sector is expected to continue its structural market trend, with Innovative Drugs as the main line and thematic opportunities rotating.
TIGERMED (300347.SZ): Has repurchased a total of 1.1337% of shares.
Gelonghui, April 2nd丨TIGERMED (300347.SZ) announced that as of March 31, 2025, the company's share repurchase special securities account has cumulatively repurchased 9,806,300 shares through centralized bidding, accounting for 1.1337% of the company's total share capital and 1.3219% of the company's total A-share capital. The highest Fill Price was 62.00 yuan/share, the lowest Fill Price was 48.17 yuan/share, and the total amount of the transaction was 0.5 billion yuan (excluding transaction fees).
Some Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Analysts Just Made A Major Cut To Next Year's Estimates
The entire pharmaceutical sector has surged sharply; what happened?
On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.
